{"prompt": "['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'Dose', 'Treatment', 'Toxicity*', 'Grade', 'Occurrence', 'Hold Treatment', 'Modification', 'Discontinuation', 'Thrombocytopenia', 'Grade 1,2, 3', 'All', 'Hold treatment', 'NA', 'NA', 'until platelets', 'recover to', '> 100000 cells/mm\u00b3', 'Grade 4', '1st', 'Hold treatment', 'Restart treatment', 'Treatment', 'until platelets', 'at:', 'discontinuation', 'recover to', 'Paclitaxel:', 'should be', '> 100000 cells/mm\u00b3', '135 mg/m\u00b2', 'considered', 'Docetaxel:', '60 mg/m\u00b2', 'Vinflunine:', '280 mg/m\u00b2', '2nd', 'Hold treatment', 'Restart treatment', 'Treatment', 'until platelets', 'at:', 'Discontinuation', 'recover to', 'Paclitaxel:', 'should be', '> 100000 cells/mm\u00b3', '100 mg/m\u00b2', 'considered', 'Docetaxel:', '50 mg/m\u00b2', 'Vinflunine:', '250 mg/m\u00b2', '3rd', 'Yes', 'NA', 'Yes', 'Anemia', 'Grade 1,2, 3', 'All', 'Until anemia', 'NA', 'NA', 'resolves to Grade 1', 'or baseline', 'Grade 4', '1st', 'Until anemia resolves', 'Restart treatment', 'Treatment', 'to Grade 1 or baseline', 'at:', 'discontinuation', 'Paclitaxel:', 'should be', '135 mg/m\u00b2', 'considered', 'Docetaxel:', '60 mg/m\u00b2', 'Vinflunine:', '280 mg/m\u00b2', '2nd', 'Until anemia resolves', 'Restart treatment', 'Treatment', 'to Grade 1 or baseline', 'at:', 'Discontinuation', 'Paclitaxel:', 'should be', '100 mg/m\u00b2', 'considered', 'Docetaxel:', '50 mg/m\u00b2', 'Vinflunine:', '250 mg/m\u00b2', '3rd', 'Yes', 'NA', 'Yes', 'Table continued on next page', '14 Sep 2020', 'Astellas', 'Page 61 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'Dose', 'Treatment', 'Toxicity*', 'Grade', 'Occurrence', 'Hold Treatment', 'Modification', 'Discontinuation', 'Nonhematological', 'Grade 1, 2', 'All', 'No', 'None', 'NA', 'toxicity and other', 'Grade 3, 4', '1st', 'Yes, until toxicity', 'Restart treatment', 'Treatment', 'hematological', 'resolves to Grade 0-1', 'at:', 'Discontinuation', 'toxicity not', 'or baseline', 'Paclitaxel:', 'should be', 'described', '135 mg/m\u00b2', 'considered', 'above. **', 'Docetaxel:', '60 mg/m\u00b2', 'Vinflunine:', '280 mg/m\u00b2', '2nd', 'Yes, until toxicity', 'Restart treatment', 'Treatment', 'resolves to Grade 0-1', 'at:', 'Discontinuation', 'or baseline', 'Paclitaxel:', 'should be', '100 mg/m\u00b2', 'considered', 'Docetaxel:', '50 mg/m\u00b2', 'Vinflunine:', '250 mg/m\u00b2', '3rd', 'Yes', 'NA', 'Yes', '*See', 'Table 7.', 'Table 8', 'and', 'Table 9 for additional dose modifications for drug-related adverse events specific to docetaxel,', 'vinflunine and paclitaxel, respectively.', '*Subjects who experience suspected severe hypersensitivity reaction to paclitaxel or vinflunine (e.g., generalized', 'rash/erythema, hypotension and/or bronchospasm, angioedema or anaphylaxis) should be discontinued from trial', 'treatment.', '*** For docetaxel, paclitaxel or vinflunine associated hematologic toxicities > Grade 3, transfusions or growth factors', 'may be used as indicated per institutional guidelines.', 'See Table 7 and Table 9 for guidelines on management of peripheral neuropathy specific to docetaxel and paclitaxel,', 'respectively.', 'NA: not applicable', '5.1.2.3 Docetaxel Dose Modifications', 'Docetaxel should not be given to subjects with total bilirubin > ULN, or to subjects with AST', 'and/or ALT > 1.5 X ULN with concomitant alkaline phosphatase > 2.5 X ULN. Subjects with', 'elevations of bilirubin or abnormalities of transaminase concurrent with alkaline phosphatase', 'are at increased risk for the development of Grade 4 neutropenia, febrile neutropenia,', 'infections, severe thrombocytopenia, severe stomatitis, severe skin toxicity, and toxic death.', 'Docetaxel should also not be given to subjects with a neutrophil count of < 1500 cells/mm\u00b3.', 'Severe fluid retention has been reported following docetaxel therapy. Subjects should be', 'premedicated with corticosteroids prior to each docetaxel injection administration to reduce', 'the incidence and severity of fluid retention. Subjects with pre-existing effusions should be', 'closely monitored from the first dose for the possible exacerbation of the effusions. Subjects', 'developing peripheral edema may be treated with standard measures, e.g., salt restriction,', 'oral diuretic(s). Dose interruptions may last up to 6 weeks (2 cycles). Dose interruptions for', \"subjects who are responding to treatment may be extended beyond 6 weeks, if the subject's\", 'toxicity does not otherwise require permanent discontinuation. Recommended dose', 'modification guidelines for subjects receiving docetaxel are detailed below in Table 7', 'Dose', '14 Sep 2020', 'Astellas', 'Page 62 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']\n\n###\n\n", "completion": "END"}